S
Scott T. Tagawa
Researcher at Cornell University
Publications - 374
Citations - 16103
Scott T. Tagawa is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 50, co-authored 290 publications receiving 11515 citations. Previous affiliations of Scott T. Tagawa include University of Southern California & Boston Medical Center.
Papers
More filters
Journal ArticleDOI
Integrative clinical genomics of advanced prostate cancer
Dan R. Robinson,Eliezer M. Van Allen,Eliezer M. Van Allen,Yi-Mi Wu,Nikolaus Schultz,Robert J. Lonigro,Juan Miguel Mosquera,Bruce Montgomery,Mary-Ellen Taplin,Colin C. Pritchard,Gerhardt Attard,Gerhardt Attard,Himisha Beltran,Wassim Abida,Robert K. Bradley,Jake Vinson,Xuhong Cao,Pankaj Vats,Lakshmi P. Kunju,Maha Hussain,Felix Y. Feng,Scott A. Tomlins,Kathleen A. Cooney,David Smith,Christine Brennan,Javed Siddiqui,Rohit Mehra,Yu Chen,Yu Chen,Dana E. Rathkopf,Dana E. Rathkopf,Michael J. Morris,Michael J. Morris,Stephen B. Solomon,Jeremy C. Durack,Victor E. Reuter,Anuradha Gopalan,Jianjiong Gao,Massimo Loda,Rosina T. Lis,Michaela Bowden,Michaela Bowden,Stephen P. Balk,Glenn C. Gaviola,Carrie Sougnez,Manaswi Gupta,Evan Y. Yu,Elahe A. Mostaghel,Heather H. Cheng,Hyojeong Mulcahy,Lawrence D. True,Stephen R. Plymate,Heidi Dvinge,Roberta Ferraldeschi,Roberta Ferraldeschi,Penny Flohr,Penny Flohr,Susana Miranda,Susana Miranda,Zafeiris Zafeiriou,Zafeiris Zafeiriou,Nina Tunariu,Nina Tunariu,Joaquin Mateo,Joaquin Mateo,Raquel Perez-Lopez,Raquel Perez-Lopez,Francesca Demichelis,Francesca Demichelis,Brian D. Robinson,Marc H. Schiffman,David M. Nanus,Scott T. Tagawa,Alexandros Sigaras,Kenneth Eng,Olivier Elemento,Andrea Sboner,Elisabeth I. Heath,Howard I. Scher,Howard I. Scher,Kenneth J. Pienta,Philip W. Kantoff,Johann S. de Bono,Johann S. de Bono,Mark A. Rubin,Peter S. Nelson,Levi A. Garraway,Levi A. Garraway,Charles L. Sawyers,Arul M. Chinnaiyan +89 more
TL;DR: This cohort study provides clinically actionable information that could impact treatment decisions for affected individuals and identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF.
Journal ArticleDOI
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran,Himisha Beltran,Davide Prandi,Juan Miguel Mosquera,Juan Miguel Mosquera,Matteo Benelli,Loredana Puca,Joanna Cyrta,Clarisse Marotz,Eugenia G. Giannopoulou,Balabhadrapatruni V. S. K. Chakravarthi,Sooryanarayana Varambally,Scott A. Tomlins,David M. Nanus,Scott T. Tagawa,Eliezer M. Van Allen,Eliezer M. Van Allen,Olivier Elemento,Olivier Elemento,Andrea Sboner,Andrea Sboner,Levi A. Garraway,Levi A. Garraway,Levi A. Garraway,Mark A. Rubin,Mark A. Rubin,Francesca Demichelis,Francesca Demichelis,Francesca Demichelis +28 more
TL;DR: Analysis of whole-exome sequencing data of metastatic biopsies from patients observed substantial genomic overlap between castration-resistant tumors that were histologically characterized as prostate adenocarcinomas and neuroendocrine prostate cancer (CRPC-NE), supporting the emergence of an alternative, 'AR-indifferent' cell state through divergent clonal evolution as a mechanism of treatment resistance in advanced prostate cancer.
Journal ArticleDOI
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Yohann Loriot,Andrea Necchi,Se Hoon Park,Jesús García-Donas,Robert Huddart,Elizabeth A. Burgess,Mark D. Fleming,A. Rezazadeh,Begoña Mellado,Sergei Varlamov,Monika Joshi,Ignacio Duran,Scott T. Tagawa,Yousef Zakharia,B. Zhong,K. Stuyckens,A. Santiago-Walker,P. De Porre,A. O'Hagan,A. Avadhani,Arlene O. Siefker-Radtke +20 more
TL;DR: The use of erdafitinib was associated with an objective tumor response in 40% of previously treated patients who had locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations.
Journal ArticleDOI
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Himisha Beltran,David S. Rickman,Kyung Park,Sung Suk Chae,Andrea Sboner,Theresa Y. MacDonald,Yuwei Wang,Karen Sheikh,Stéphane Terry,Scott T. Tagawa,Rajiv Dhir,Joel B. Nelson,Alexandre de la Taille,Yves Allory,Mark Gerstein,Sven Perner,Kenneth J. Pienta,Arul M. Chinnaiyan,Arul M. Chinnaiyan,Yuzhuo Wang,Colin Collins,Martin E. Gleave,Francesca Demichelis,Francesca Demichelis,David M. Nanus,Mark A. Rubin +25 more
TL;DR: There was dramatic and enhanced sensitivity of NEPC (and MYCN overexpressing PCA) to Aurora kinase inhibitor therapy both in vitro and in vivo, with complete suppression of neuroendocrine marker expression following treatment.
Journal ArticleDOI
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Oliver Sartor,Johann S. de Bono,Kim N. Chi,Karim Fizazi,Ken Herrmann,Kambiz Rahbar,Scott T. Tagawa,Luke T. Nordquist,Nitin Vaishampayan,Ghassan El-Haddad,Chandler H Park,Tomasz M. Beer,Alison Armour,Wendy J Pérez-Contreras,Michelle DeSilvio,Euloge Kpamegan,Germo Gericke,Richard A. Messmann,Michael J. Morris,Bernd J. Krause,Vision Investigators +20 more
TL;DR: In this paper, Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer and remains fatal despite recent advances in medical technology.